MIAMI, Feb. 13, 2008 (PRIME NEWSWIRE) -- Galea Life Sciences, Inc. (Pink Sheets:GLSN) announces that its wholly-owned subsidiary, BioSource Therapeutics, Inc. (BST), has named Edward Martin to its Board of Directors. BST is the maker of Nutraplete(tm) Therapeutic Drink Mix, the first dietary supplement product designed specifically for people living with HIV/AIDS.
"Mr. Martin's extensive international experience with health, economic and marketing initiatives promises to enhance BST's current and future development on a global scale," said David Miller, President, BioSource Therapeutics, Inc. "We are delighted that Mr. Martin will be joining BST's Board of Directors where we can incorporate his unique strengths as part of our Nutraplete team."
Edward Martin is the Global Director Breakthrough Innovation, International Research and Corporate Social Responsibility for The Hershey Foods Company. He is also the founder and former Chairman and CEO of Triple Win International (www.triplewininternational.com), a company dedicated to maximizing ROI for corporations while supporting global health and poverty initiatives. Mr. Martin brings many years of experience with top Fortune 500 organizations, including: Kellogg's, Coca-Cola, Citibank and Ford Motor Company. His expertise covers markets in The Americas, Europe, Africa, the Middle East and Asia. Mr. Martin serves as a senior advisor to the Millennium Project, which is part of the World Federation of United Nations Associations. Its core focus is to end extreme poverty and provide educational and sustainable economic opportunities in developing global markets. He has been elected to the Boards of organizations such as the Medical Institute, Health Store Foundation, International Business Advisory Board EMU, Malaria Foundation, and is a Senior Advisor to Health People in the South Bronx. He is a key member of the Harvard AIDS Prevention Research Project and holds a BA from the University of Michigan, Dearborn and an MBA from Wayne State University.
"I am honored to be named to the Board of Directors of BioSource Therapeutics, Inc.," said Mr. Martin. "David Miller's vision, focus and dedication to supporting those with HIV/AIDS has been inspiring. I look forward to joining this organization of dedicated scientists and business professionals to deliver products that are designed to save lives, and to improve the quality of life for many others. I have no doubt that BST will become the 'gold standard' on how a business can operate to benefit shareholders and create a positive, lasting impact on the community."
About Nutraplete
Nutraplete is the first therapeutic dietary supplement designed specifically for people living with HIV/AIDS. It is a multi-nutritional supplement, designed to address AIDS Wasting Syndrome. It works in conjunction with antiviral therapies and assists patients in the adherence and tolerance of treatments. Nutraplete is a "functional food" that encourages the restoration of lean body mass, can inhibit pro-oxidative stress, and improves immune function. Nutraplete is available by prescription, and has started the application process for inclusion with Medicaid and AIDS Drugs Assistance Program (ADAP) formularies. Nutraplete is distributed exclusively in the U.S. by Allion Healthcare, Inc. (NASDAQ: ALLI) under its MOMS Pharmacy trade name. www.momspharmacy.com.
For more information: www.nutraplete.com
About Galea Life Sciences, Inc.
Galea Life Sciences, Inc. (Pink Sheets:GLSN) is currently a non-reporting over-the-counter, publicly traded company. GLSN identifies and acquires new and innovative nutraceutical product and dietary supplement companies with outstanding growth potential. GLSN's focus is in the emerging scientific field of advanced nutritional supplements designed to support traditional medical treatments and therapies. BioSource Therapeutics, Inc. (BST), a GLSN subsidiary, is an entrepreneurial life sciences company. BST specializes in the formulation, manufacturing, marketing and distribution of innovative dietary supplements that benefit people undergoing medical treatments and therapies.
Certain statements in this release constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words ``forecast,'' ``project,'' ``intend,'' ``expect'' ``should,'' ``would,'' and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (finance or operating) or achievements to differ from future results, performance (financing and operating) or achievements expressed or implied by such forward-looking statements. Statements herein express management's beliefs and expectations regarding future performance and are forward-looking and involve risks and uncertainties, including, but not limited to, the ability to negotiate outstanding prior debts of acquired companies; properly identify acquisition partners; adequately perform due diligence; manage and integrate acquired businesses; react to quarterly fluctuations in results; raise working capital and secure other financing; respond to competition and rapidly changing technology; deal with market and stock price fluctuations; and other risks.
The Galea Life Sciences logo is available athttp://www.primenewswire.com/newsroom/prs/?pkgid=4489